Cizzle Biotechnology (LON:CIZ) Trading Down 2.3%

Shares of Cizzle Biotechnology Holdings Plc (LON:CIZGet Free Report) fell 2.3% during trading on Friday . The company traded as low as GBX 2.02 ($0.03) and last traded at GBX 2.10 ($0.03). 1,018,990 shares were traded during mid-day trading, a decline of 8% from the average session volume of 1,111,099 shares. The stock had previously closed at GBX 2.15 ($0.03).

Cizzle Biotechnology Trading Down 2.3 %

The stock’s 50 day moving average price is GBX 2.33 and its 200 day moving average price is GBX 2.15. The firm has a market cap of £7.64 million, a PE ratio of 210.00 and a beta of 0.42.

Institutional Investors Weigh In On Cizzle Biotechnology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CIZ. Jane Street Group LLC increased its stake in Cizzle Biotechnology by 340.8% during the 1st quarter. Jane Street Group LLC now owns 102,626 shares of the company’s stock worth $3,192,000 after buying an additional 79,342 shares during the period. Atria Wealth Solutions Inc. purchased a new stake in Cizzle Biotechnology during the 1st quarter worth $535,000. Ameriprise Financial Inc. increased its stake in Cizzle Biotechnology by 5.3% during the 1st quarter. Ameriprise Financial Inc. now owns 136,700 shares of the company’s stock worth $4,251,000 after buying an additional 6,858 shares during the period. Bank of America Corp DE increased its stake in Cizzle Biotechnology by 4.5% during the 1st quarter. Bank of America Corp DE now owns 109,452 shares of the company’s stock worth $3,404,000 after buying an additional 4,664 shares during the period. Finally, Raymond James Financial Services Advisors Inc. increased its stake in Cizzle Biotechnology by 19.4% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 25,269 shares of the company’s stock worth $820,000 after buying an additional 4,107 shares during the period.

Cizzle Biotechnology Company Profile

(Get Free Report)

Cizzle Biotechnology Holdings Plc, together with its subsidiaries, engages in the development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer in the United Kingdom. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021.

Recommended Stories

Receive News & Ratings for Cizzle Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cizzle Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.